Editors’ Picks, February 2025: Improving CAR T, Studying Breast Cancer Risk, and More
This month, the editors of AACR's journals show their love for studies about CAR T-cell efficacy, breast cancer risk, and more.
Progress Against Cancer
This month, the editors of AACR's journals show their love for studies about CAR T-cell efficacy, breast cancer risk, and more.
Radiation plus immunotherapy may help some patients with invasive bladder cancer keep their bladders. Patients with localized muscle-invasive bladder cancer (MIBC), or bladder cancer that has spread through the lining of the bladder and...
The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for the treatment of adult...
Pesticide firms try to block cancer-related lawsuits, and cancer pain leads to greater tobacco and cannabis use.
Researchers are examining ways to make treatments more targeted to each type of biliary tract cancer or to each patient.
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris), in...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for the treatment of patients with neurofibromatosis...
Researchers explore musical toxicity from cancer treatment, and kidney cancer vaccine shows potential in early trial.
FDA approves an antibody-drug conjugate for people with HER2-ultralow breast cancer, and historic redlining practices have a lingering impact on cancer outcomes.
As winter marches on, let’s dive into the cool articles highlighted this month by the editors of the AACR journals. Grab a blanket and keep reading to learn how nicotine levels in e-cigarettes impact...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now